Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study [0.03%]
卡博替尼联合纳武利尤单抗治疗晚期非透明细胞肾癌的疗效和安全性：一项全国多中心研究
Chang Gon Kim,Junkyu Kim,In-Ho Kim et al.
Chang Gon Kim et al.
Non-clear cell renal cell carcinoma (nccRCC) represents a biologically heterogeneous group of tumors for which optimal systemic treatment strategies remain poorly defined despite recent therapeutic advances. To address this gap, we evaluate...
Multicenter Study
Oncoimmunology. 2026 Dec 31;15(1):2694175. DOI:10.1080/2162402X.2026.2694175 2026
Early neutrophil infiltration promotes TRIMELVax-induced antitumor immunity by linking local inflammation to tumor control [0.03%]
早期中性粒细胞浸润通过连接局部炎症和肿瘤控制来促进TRIMELVax诱导的抗肿瘤免疫反应
Amarilis Pérez-Baños,María Alejandra Gleisner,Andrés Tittarelli et al.
Amarilis Pérez-Baños et al.
Enhancing innate-adaptive immune crosstalk is key for improving cancer vaccine efficacy. TRIMELVax is a heat shock-conditioned whole-tumor-cell vaccine combining xenogeneic melanoma cell lysate, syngeneic B16F10 melanoma cell lysate, and Co...
Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma [0.03%]
序贯阿昔替尼和 survivin 疫苗治疗解除肾癌的 PD-1 免疫治疗耐药性
Fanny Méjean,Thi Tran,Maya Merabet et al.
Fanny Méjean et al.
Despite significant progress achieved by combining VEGFR tyrosine-kinase inhibitors (TKIs) with immune checkpoint inhibitors (ICIs), complete responses remain rare in metastatic renal cell carcinoma (mRCC), highlighting the need for strateg...
Purinergic activity of circulating extracellular vesicles associates with disease progression in melanoma [0.03%]
循环外泌体嘌呤活性与黑色素瘤疾病进展相关的研究
Yana G Najjar,Chang Sook Hong,Elizabeth V Menshikova et al.
Yana G Najjar et al.
Extracellular vesicles (EVs) produced by melanoma cells (MTEX) carry ecto-nucleotidases, CD39/CD73, on their surface membrane, produce adenosine (ADO), and deliver it to immune recipient cells, inducing immune suppression. Based on studies ...
Pooled analysis of 2 clinical trials of first-line chemoimmunotherapy for metastatic microsatellite stable colorectal cancer MEDITREME and METIMMOX studies [0.03%]
一线化疗免疫疗法治疗转移性微卫星稳定型结直肠癌的Meta分析：MEDITREME和METIMMOX研究
Caroline Truntzer,Marion Thibaudin,Paula Anna Bousquet et al.
Caroline Truntzer et al.
Background: Colorectal cancer with microsatellite stable (MSS) status is intrinsically resistant to immune checkpoint inhibitor monotherapy targeting PD-1 or PD-L1. However, emerging evidence suggests that chemotherapies ...
Tumor-educated macrophages promote cytokine-driven lung colonization in triple-negative breast cancer [0.03%]
肿瘤教育巨噬细胞促进三阴性乳腺癌肺转移中的细胞因子驱动的肺部定植
María Rosado-Sanz,Nuria Martínez-Alarcón,Michaël H Meel et al.
María Rosado-Sanz et al.
Triple-negative breast cancer (TNBC) remains one of the most lethal breast cancer subtypes, driven by early dissemination and resistance to therapy. Here, we reveal a macrophage-centered cytokine circuit that fuels TNBC metastasis and immun...
CD4 + cell depletion accelerates dendritic cell migration and enhances resident dendritic cell proliferation in tumor-draining lymph nodes [0.03%]
CD4+细胞耗竭加速了肿瘤引流淋巴结中树突状细胞的迁移并增强常驻树突状细胞的增殖
Taiki Moriya,Mayuko Hashimoto,Mizuki Ueda et al.
Taiki Moriya et al.
Depletion of CD4+ cells during an anti-tumor immune response promotes tumor regression and accelerates proliferation of tumor-antigen-specific CD8+ T cells in draining lymph nodes (dLNs). However, the effect of the depletion on inter-organ ...
FTL008.16, a 5T4-Conditional 4-1BB bispecific antibody, potently enhances antitumor immunity via tumor-directed t-cell activation [0.03%]
FTL008.16是一种条件性的5T4-4-1BB双特异性抗体，可通过肿瘤导向的T细胞活化有效增强抗肿瘤免疫反应
Shuang Liu,Ziqing Ren,Yongyan Tu et al.
Shuang Liu et al.
The clinical development of 4-1BB agonists for cancer immunotherapy has been constrained by dose-limiting toxicities, particularly hepatotoxicity. To overcome this challenge, we developed FTL008.16, a novel bispecific antibody targeting 4-1...
CXCL13-expressing CD4+ T cells coordinate the lymphocytes triad to promote the anti-tumor immunity in NSCLC [0.03%]
NSCLC中 CXCL13⁺CD4⁺T细胞协调淋巴细胞三联体促进抗肿瘤免疫
Danping Liu,Jiajun Luo,Wei Guo et al.
Danping Liu et al.
CD4+ T cells are indispensable for CD8+ T cells-mediated anti-tumor immunity, while little is known about how CD4+ T cells coordinate with other cells to promote CD8+ T cells activity. In this study, by coupling single-cell RNA sequencing (...
Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis [0.03%]
局部递送SBRT和IL-12可调节小鼠PDAC肿瘤的造血干细胞分化方向
Tara G Vrooman,Emily R Quarato,Gary Hannon et al.
Tara G Vrooman et al.
Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to...